CytRx Corporation (CYTR) Receives Orphan Medicinal Product Designation From European Commission (EC) For Aldoxorubicin In Soft Tissue Sarcoma
3/31/2014 8:04:35 AM
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.
Help employers find you! Check out all the jobs and post your resume.
comments powered by